Considerations for talking to your patients about using bypassing agents while they are on HEMLIBRA® prophylaxis

Educate patients and caregivers to think differently about treating breakthrough bleeds
  • Discuss the signs and symptoms of bleeds that require bypassing agents and when to seek medical advice before treating these bleeds
  • Explain that HEMLIBRA increases the potential for blood to clot, so it’s important to discuss the use of bypassing agents prior to starting HEMLIBRA prophylaxis
  • Describe the potential risks of TMA and thromboembolism if aPCC is administered while taking HEMLIBRA
  • Encourage patients to update emergency medical information and to advise any healthcare provider about potential risks with concomitant aPCC
Make a plan with your patients and caregivers for how to appropriately use bypassing agents when using HEMLIBRA
  • Consider the benefits and risks if aPCC must be used in a patient taking HEMLIBRA
  • Ensure patients and caregivers know to consult their healthcare provider if aPCC is required in cumulative doses exceeding 100 U/kg
Monitor for TMA and thromboembolism if administering aPCC
  • Discuss the signs and symptoms of TMA and thromboembolism
  • Ensure patients and caregivers know to contact their healthcare provider and seek immediate medical treatment if they suspect signs or symtpoms of TMA or thromboembolism
  • Immediately discontinue aPCC and suspend dosing of HEMLIBRA if clinical symptoms, imaging, or laboratory findings consistent with these events occur, and manage as clinically indicated
  • Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of these events on a case-by-case basis

Treating Breakthrough Bleeds

Guidelines for addressing breakthrough bleeds

Dosing Calculator

Help calculate the dosage for your HEMLIBRA patient

HEMLIBRA Laboratory Monitoring Information

Considerations for using laboratory tests to monitor patients taking HEMLIBRA